![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to advance the Company’s lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand the Company’s immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform.
Lead Product(s): ATTO-1310
Therapeutic Area: Dermatology Product Name: ATTO-1310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs Alternatives
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 09, 2024